A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children
DOI: https://doi.org/10.2147/dddt.s457761
IF: 4.3188
2024-03-28
Drug Design Development and Therapy
Abstract:Mingyue Wang, 1– 4 Xing-Hua Gao, 1– 4 Li Zhang 1 1 Department of Dermatology, the First Hospital of China Medical University, Shenyang, 110001, People's Republic of China; 2 NHC Key Laboratory of Immunodermatology, China Medical University, Shenyang, People's Republic of China; 3 Key Laboratory of Immunodermatology, China Medical University, Ministry of Education, Shenyang, People's Republic of China; 4 National and Local Joint Engineering Research Center of Immunodermatological Theranostics, Shenyang, People's Republic of China Correspondence: Li Zhang, Department of Dermatology, the First Hospital of China Medical University, Shenyang, 110001, People's Republic of China, Email Atopic dermatitis (AD), a common pruritic and chronic inflammatory skin disease, has a major impact on a patient's quality of life. It is characterized by dry, itchy, and eczema-like rashes. AD is more prevalent in young children and has been linked to a variety of other allergy disorders. Traditional drug therapy has certain limitations for treating young children with AD. However, biologics have good clinical application prospects in the medical treatment of young patients. Dupilumab, a fully human monoclonal antibody, specifically binds to the IL-4 Rα subunit, inhibiting IL-4 and IL-13 signaling and blocking the occurrence of type 2 inflammatory response. It has a good effect on treating infants and children with moderate-to-severe AD. This review explores the safety and efficacy of dupilumab in the treatment of AD in infants and children and the impact of early intervention on AD progression, with the aim of informing clinical practice in the use of dupilumab for the treatment of young patients with AD. Keywords: atopic dermatitis, dupilumab, infant, child, treatment Atopic dermatitis (AD), a common chronic inflammatory skin disease, is characterized by recurrent eczematous lesions and intense itching. AD can occur at any age, with most cases starting in infancy or childhood, becoming more common in children aged 3–6 months, and developing in adulthood. The prevalence of AD is currently increasing globally in all age groups, ranging from 2.7% to 20.1% in children in different countries. 1–4 The pathogenesis of AD is significantly influenced by genetic factors. Mutations in filaggrin (FLG) impair the functioning of epidermal barriers, which is manifested by increased transepidermal water loss (TWEL), increased contact with allergens, and adherence and colonization by S. aureus. In addition, damaged skin barriers make them susceptible to excessive immune-inflammatory responses, which can induce itchy skin. 5–7 The immune-inflammatory response is the central key to the pathogenesis of AD, which is mainly characterized by the production of specific IgE antibodies by Th2 cells and B cells. Damage to the lipid membranes of the skin caused by low expression of FLG and loricrin (LOR) also facilitates the penetration of antigens, allergens, and pollutants into the stratum corneum of the skin, damaging the epidermal barrier. Alarmins released from this disruption of the epidermal barrier, such as IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), activate the type 2 innate lymphoid cells (ILC2s) and dendritic cells (DCs) and ILC2s, causing them to produce IL-5 and IL-13, which in turn activate Th2 cells and eosinophils. Th2 cells that are activated release IL-4 and IL-13, which stimulate B cell IgE class switching and generate IgE specific to antigens through transcription activator and signal transduction pathways. When external antigens and allergens come into interaction with IgE on the mast cell surface, mast cell degranulation releases histamine to trigger itching. 8–10 Although genetic and immunological factors are important in the development of atopic dermatitis, the role of environmental factors cannot be ignored as the global prevalence of the disease increases. Lifestyle changes, climate change, and allergenic stimuli may all contribute to the development of AD. In addition, AD is often associated with other atopic disorders, such as food allergies, asthma, and allergic rhinitis. These atopic comorbidities, with the sequential development from infancy through adolescence, typically begin with AD. This phenomenon is defined as atopic march, which reflects the sequential progression of different allergic diseases and the temporal relationship of the natural history of the disease. Mechanisms of the atopic march may be related to the circulating spread of inflammatory factors and specific IGE production. 11–15 Due to the particularity of infants and children, a high body surface area to body weight ratio may cause the skin to absorb medications more readily, and the use of traditional systemic medications may -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal